214 related articles for article (PubMed ID: 27233940)
41. E-cadherin immunohistochemistry in breast pathology: uses and pitfalls.
Canas-Marques R; Schnitt SJ
Histopathology; 2016 Jan; 68(1):57-69. PubMed ID: 26768029
[TBL] [Abstract][Full Text] [Related]
42. The influence of additional surgical margins on the total specimen volume excised and the reoperative rate after breast-conserving surgery.
Huston TL; Pigalarga R; Osborne MP; Tousimis E
Am J Surg; 2006 Oct; 192(4):509-12. PubMed ID: 16978962
[TBL] [Abstract][Full Text] [Related]
43. Role of re-excision for positive and close resection margins in patients treated with breast-conserving surgery.
Biglia N; Ponzone R; Bounous VE; Mariani LL; Maggiorotto F; Benevelli C; Liberale V; Ottino MC; Sismondi P
Breast; 2014 Dec; 23(6):870-5. PubMed ID: 25305040
[TBL] [Abstract][Full Text] [Related]
44. [Expression of E-cadherine as a differential diagnostic fest for lobular infiltrative breast cancers].
Chipysheva TA; Ermilova VD; Vishnevskaia IaV; Vasil'ev IuM
Arkh Patol; 2005; 67(6):24-7. PubMed ID: 16405017
[TBL] [Abstract][Full Text] [Related]
45. Invasive lobular carcinoma in a hypoplastic breast.
Bassarova AV; Sedloev T; Christova SL; Trifonov DY; Nesland JM
Ultrastruct Pathol; 2002; 26(6):411-4. PubMed ID: 12537766
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer.
Debald M; Kaiser C; Abramian A; Schildhaus HU; Locher P; Wolfgarten M; Kuhn W; Braun M
Anticancer Res; 2013 May; 33(5):1971-5. PubMed ID: 23645745
[TBL] [Abstract][Full Text] [Related]
47. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.
Vincent-Salomon A; Hajage D; Rouquette A; Cédenot A; Gruel N; Alran S; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Kirova Y
Breast; 2012 Jun; 21(3):380-3. PubMed ID: 22531230
[TBL] [Abstract][Full Text] [Related]
48. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.
Joh JE; Esposito NN; Kiluk JV; Laronga C; Khakpour N; Soliman H; Catherine Lee M
Breast J; 2012; 18(6):569-74. PubMed ID: 23034096
[TBL] [Abstract][Full Text] [Related]
49. Histology and immunophenotype of invasive lobular breast cancer. daily practice and pitfalls.
Varga Z; Mallon E
Breast Dis; 2008-2009; 30():15-9. PubMed ID: 19850991
[TBL] [Abstract][Full Text] [Related]
50. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
51. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast.
Palacios J; Sarrió D; García-Macias MC; Bryant B; Sobel ME; Merino MJ
Mod Pathol; 2003 Jul; 16(7):674-8. PubMed ID: 12861063
[TBL] [Abstract][Full Text] [Related]
52. Predictors of Residual Tumor in Breast-Conserving Therapy.
Rath MG; Uhlmann L; Heil J; Domschke C; Roth Z; Sinn HP; Marme F; Scharf A; Schneeweiss A; Kieser M; Sohn C; Rom J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S451-8. PubMed ID: 26224405
[TBL] [Abstract][Full Text] [Related]
53. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
54. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer.
Xie ZM; Li LS; Laquet C; Penault-Llorca F; Uhrhammer N; Xie XM; Bignon YJ
Cancer; 2011 Jul; 117(14):3112-7. PubMed ID: 21271559
[TBL] [Abstract][Full Text] [Related]
55. Orbital metastases of invasive lobular breast carcinoma.
Tsagkaraki IM; Kourouniotis CD; Gomatou GL; Syrigos NK; Kotteas EA
Breast Dis; 2019; 38(3-4):85-91. PubMed ID: 31640079
[TBL] [Abstract][Full Text] [Related]
56. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
[TBL] [Abstract][Full Text] [Related]
57. Identifying patients at risk of compromised margins following breast conservation for lobular carcinoma.
Dillon MF; Hill AD; Fleming FJ; O'Doherty A; Quinn CM; McDermott EW; O'Higgins N
Am J Surg; 2006 Feb; 191(2):201-5. PubMed ID: 16442946
[TBL] [Abstract][Full Text] [Related]
58. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
59. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
Palacios J; Benito N; Pizarro A; Suárez A; Espada J; Cano A; Gamallo C
Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041
[TBL] [Abstract][Full Text] [Related]
60. [Carcinoma in situ of the breast].
Laenkholm AV; Hoffmann J; Rank FE
Ugeskr Laeger; 2007 Sep; 169(37):3087-90. PubMed ID: 17877955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
